According to latest report, the global chronic idiopathic constipation treatment market reached value at US$ 8 Bn in 2020 projected to hit around US$ 16 billion by 2030, expanding growth at a CAGR of 7.1% from 2021 to 2030.
Constipation is a common condition that occurs when bowel movement becomes less frequent and stools become difficult to pass. Chronic idiopathic constipation is a type of constipation. It is categorized by infrequent stools that are often difficult to pass. It is specifically affects older adults and women. The global chronic idiopathic constipation treatment market is expanding due to significant investments by key players. Investments by key players to strengthen their product portfolios through acquisitions, mergers, and collaborations create significant opportunities in the market. The adoption of newer therapeutics is fueling the demand for advanced products. This represents a new business development opportunity.
Focus on R&D to Drive Chronic Idiopathic Constipation Treatment Market
Increase in R&D activities and expenditure on new products and therapeutics development are expected to drive the chronic idiopathic constipation treatment market. Moreover, rise in pharmaceutical R&D budgets by both governments and private players to support new product and technology development is anticipated to drive the demand for chronic idiopathic constipation treatment products.
Rise in Healthcare Spending and Improvements in Healthcare Infrastructure Propel Market
Increase in the number of patients with chronic idiopathic constipation boosts adoption of newer products. Patients are more aware and proactive about their health, and are willing to seek effective treatment. Hence, rise in healthcare spending on constipation is likely to boost the market. An article published in the American Journal of Managed Care in 2007 stated that people in the U.S. spent more than US$ 800 million on laxatives. Chronic idiopathic constipation has a significant impact on the healthcare system, and it accounted for 3.92% of all ambulatory care visits in the U.S. in 2014.
In terms of type, the global chronic idiopathic constipation treatment market has been classified into Serotonin-4 (5-Ht4) Receptor Agonist, Guanylate Cyclase-C Agonist, laxatives, stimulants, and others. The stimulants segment accounted for a major share of the market. It is likely to maintain its dominance during the forecast period. Effectiveness of stimulant laxatives in the treatment of constipation is increasing the use of products and subsequently, driving the segment.
In terms of route of administration, the global chronic idiopathic constipation treatment market has been divided into oral and rectal. The oral segment dominated the global market in 2020. It is anticipated to expand at a rapid pace during the forecast period. The introduction of new formulations administered through the oral route is likely to fuel the segment. For instance, in 2020, the U.S. Food and Drug Administration (FDA) has approved lactitol (Pizensy) osmotic laxative recommended dosage of 20 grams orally, daily, for the treatment of CIC.
In terms of distribution channel, the global chronic idiopathic constipation treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Surge in number of retail pharmacies due to preference for distribution through retail pharmacy is likely to propel the segment.
North America dominated the global chronic idiopathic constipation treatment market in 2020. The trend is anticipated to continue during the forecast period. Strategies adopted by key players, such as product approval & launch and mergers & acquisitions, well-established healthcare infrastructure, and early adoption of advanced therapeutics boost the chronic idiopathic constipation treatment market in the region.
Asia Pacific is likely to be a highly lucrative market for chronic idiopathic constipation treatment. The market in the region is expected to expand at a high CAGR during the forecast period. Government initiatives in developing countries toward modernization of healthcare infrastructure and rise in awareness about advanced therapeutics are key factors that are anticipated to fuel the chronic idiopathic constipation treatment market in Asia Pacific.
Key players in the global chronic idiopathic constipation treatment market include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company, SEBELA PHARMACEUTICALS, Ironwood Pharmaceuticals, Inc., Albireo Pharma, Inc., Sucampo Pharmaceuticals, Inc. (Mallinckrodt), and Janssen Pharmaceuticals, Inc. (Johnson & Johnson).
This report focuses on chronic idiopathic constipation treatment market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall chronic idiopathic constipation treatment market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global chronic idiopathic constipation treatment market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global chronic idiopathic constipation treatment market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the chronic idiopathic constipation treatment market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
In this study, the years considered to estimate the market size of chronic idiopathic constipation treatment are as follows:
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global chronic idiopathic constipation treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
The research methodology adopted by analysts for compiling the global chronic idiopathic constipation treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global chronic idiopathic constipation treatment market.
The study objectives of this report are: